Active Biotech: New Results from Naptumomab
Research Note
2024-05-28
09:44
Redeye comments on the readout from the phase IIa study of naptumomab in combination with docetaxel in lung cancer conducted by NeoTX.
RR
Richard Ramanius
Disclosures and disclaimers